Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer, HER2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)WithdrawnNCT03811418
What this trial is testing

Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Who this might be right for
Advanced Breast CancerHER2-positive Breast Cancer
iOMEDICO AG
Testing effectiveness (Phase 2)Ended earlyNCT04066790
What this trial is testing

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 12
Large-scale testing (Phase 3)Active Not RecruitingNCT06635447
What this trial is testing

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Who this might be right for
Breast Cancer
AstraZeneca 293
Testing effectiveness (Phase 2)Study completedNCT00405938
What this trial is testing

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast Neoplasms
SCRI Development Innovations, LLC 79
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07367178
What this trial is testing

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

Who this might be right for
Breast CancerAdvanced HR+/HER2- Breast CancerAdvanced Triple-Negative Breast Cancer
MedSIR 30
Early research (Phase 1)Active Not RecruitingNCT06328738
What this trial is testing

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2 Positive Solid Tumors+2 more
Enliven Therapeutics 275
Early research (Phase 1)Active Not RecruitingNCT06691035
What this trial is testing

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer Metastatic Breast CancerHER2-negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 18
Early research (Phase 1)Study completedNCT00028535
What this trial is testing

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Who this might be right for
Male Breast CancerRecurrent Breast CancerRecurrent Endometrial Carcinoma+4 more
National Cancer Institute (NCI) 18
Early research (Phase 1)WithdrawnNCT02569489
What this trial is testing

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Who this might be right for
Breast Cancer
HUYABIO International, LLC.
Large-scale testing (Phase 3)Ended earlyNCT03326674
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 685
Testing effectiveness (Phase 2)Ended earlyNCT00880009
What this trial is testing

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 16
Testing effectiveness (Phase 2)Study completedNCT02339532
What this trial is testing

Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

Who this might be right for
Breast Cancer
UNICANCER 86
Testing effectiveness (Phase 2)Ended earlyNCT00903006
What this trial is testing

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT04920708
What this trial is testing

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Who this might be right for
Metastatic Breast CancerER+ Breast CancerAdvanced Breast Cancer
Royal Marsden NHS Foundation Trust 57
Large-scale testing (Phase 3)Active Not RecruitingNCT04975308
What this trial is testing

Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 874
Testing effectiveness (Phase 2)Looking for participantsNCT05837455
What this trial is testing

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Who this might be right for
Breast CancerCancer of the Breast
Washington University School of Medicine 81
Testing effectiveness (Phase 2)UnknownNCT02396108
What this trial is testing

Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
National University Hospital, Singapore 55
Testing effectiveness (Phase 2)Study completedNCT00258960
What this trial is testing

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 49
Testing effectiveness (Phase 2)WithdrawnNCT03644589
What this trial is testing

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMetastatic Breast Cancer+3 more
University of Washington
Not applicableStudy completedNCT07223476
What this trial is testing

Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,926
Next Page